Northeast Biodefense Center

东北生物防御中心(NBC)是一个由28个学术和研究机构(其中许多机构在纽约大都市区附近)以及13个总部设在美国的政府和国际组织的350名研究人员组成的联盟。在过去的5年里，NBC的调查人员展示了他们在专注于生物防御和新出现的传染病以及应急准备的研究和培训计划中跨学科和机构边界合作的承诺。生产力的证据包括&gt；160种出版物、15项发明披露、13项专利申请和5项产品开发许可证。此次更新将包括42名调查人员和32个研究项目，分为6个科学主题领域：被动免疫疗法(主席：Arturo Casadevall，爱因斯坦)；疫苗(主席：约翰·罗斯，耶鲁大学)；诊断学和病原体发现(主席：Ian Lipkin，哥伦比亚大学)；治疗学(主席：查尔斯·赖斯，洛克菲勒和霍华德·舒曼，哥伦比亚，)；先天免疫(主席：David Levy，纽约大学和Adolfo Garcia-Sastre，西奈)，以及微生物致病(主席：Jorge E.Galan，耶鲁大学和Jorge Benach，Stony Book)。生物技术和制药合作伙伴参加了诊断和病原体发现(Agilent、Akonni、Cepheid、Xynostics、454 Life Science)、治疗(Prosetta、Snowdon)和被动免疫疗法(Regeneron)主题。这些产业联系不仅提供了智力资本和资源，而且还为将发现从NBC实验室转移到更大的舞台上提供了一条途径，在那里它们可以为人类的健康和福利做出贡献。额外的力量来自与国家和国际公共卫生机构的关系，这些机构提供独特的机会，获得洞察力和临床材料(如诊断样本和PBMC)，使原本无法开展的工作得以开展。核心设施将包括蛋白质表达、动物模型和蛋白质组学。我们还将投资于发展项目(创新试点项目)以及职业发展和培训计划，其中包括个人和团体职业发展奖。作为一个设在公共卫生学院和国家卫生部的中心，NBC对应急准备有着坚定的承诺和实际的理解。

The Northeast Biodefense Center (NBC) is a consortium of >350 investigators in 28 academic and research institutions (many of them in close proximity to one another in the greater NYC metro area), and 13 US based governmental and international organizations. Over the past 5 years, NBC investigators have demonstrated their commitment to working together across disciplines and institutional boundaries in research and training programs focused on biodefense and emerging infectious diseases as well as emergency preparedness. Evidence of productivity includes >160 publications, 15 invention disclosures, 13 patent applications and 5 licenses for product development. This renewal will comprise 42 investigators and 32 research projects organized into 6 scientific theme areas: Passive Immunotherapeutics (chair: Arturo Casadevall, Einstein); Vaccines (chair: John Rose, Yale); Diagnostics and Pathogen Discovery (chair: Ian Lipkin, Columbia); Therapeutics (chairs: Charles Rice, Rockefeller and Howard Shuman, Columbia,); Innate Immunity (chairs: David Levy, NYU, and Adolfo Garcia-Sastre, Sinai), and Microbial Pathogenesis (chairs: Jorge E. Galan, Yale, and Jorge Benach, Stony Book). Biotechnology and pharmaceutical collaborators are represented in the Diagnostics and Pathogen Discovery (Agilent, Akonni, Cepheid, Xynostics, 454 Life Sciences), Therapeutics (Prosetta, Snowdon), and Passive Immunotherapeutics (Regeneron) themes. These industrial links provide not only intellectual capital and resources but also a path for moving discoveries from NBC laboratories to a larger arena where they can contribute to human health and welfare. Additional strength derives from relationships with national and international public health agencies that provide unique access to insights and clinical materials (such as diagnostic samples and PBMC) that enable work that could not otherwise be pursuec. Core facilities will include Protein Expression, Animal Models, and Proteomics. We will also invest in Developmental Projects (innovative pilot projects) and in Career Development and Training Programs that include individual and group career development awards. As a Center based in a School of Public Health and a State Department of Health, the NBC has a firm commitment to and practical understanding of Emergency Preparedness.